𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol

✍ Scribed by Ilveskoski, Ismo; Saarinen, Ulla M.; Wiklund, Tom; Perkkiö, Mikko; Salmi, Toivo T.; Lanning, Marjatta; Mäkipernaa, Anne; Pihko, Helena

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
481 KB
Volume
27
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Background. Adjuvant chemotherapy has improved the outcome of childhood malignant brain tumors in large randomized trials. With increasing survival rates, treatment toxicity has become a matter of concern. Radiation therapy and cisplatinum are known to be ototoxic.

Methods. We evaluated the incidence and factors predisposing to ototoxicity in children treated with the "8 in l " chemotherapy protocol in Finland during 1986-1993. Thirtyfive of the 82 children survived for at least 1 year after diagnosis. Thirty of these children were old enough to have an audiogram.

Results. Seventeen of the 30 children had normal hearing, seven had hearing loss at high frequencies, and six (20%) had severe hearing loss in the speech range. The risk factors for severe hearing loss were young age, a high cumulative dose of cisplatinum, and deteriorating renal function. In the presence of these factors, the risk of severe hearing loss was over 50%. Hearing loss at high frequencies could occur after low cumulative doses of cisplatinum, but severe hearing loss correlated with high cumulative doses.

Conclusions. Cisplatinum-induced hearing loss at high frequencies is common, but hearing loss in the speech range also occurs, particularly in children with predisposing factors, and may progress insidiously and rapidly. Therefore a hearing test before each "8 in 1" course is important.

📜 SIMILAR VOLUMES

Hearing loss in children with brain tumo
Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue
✍ Freilich, Ronnie J.; Kraus, Dennis H.; Budnick, Amy S.; Bayer, Lisa A.; Finlay, 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 602 KB

Carboplatin is less ototoxic than cisplatin, but ototoxicity may occur with carboplatin at higher doses. We evaluated hearing in children with brain tumors treated with conventional dose cisplatin followed by highdose carboplatin. Children under 6 years of age, newly diagnosed with brain tumors, wer

Treatment of malignant scala posterior b
Treatment of malignant scala posterior brain tumors in children: The chemotherapy of relapsed medulloblastoma with a dibromdulcitol containing drug regime and pharmacokinetic studies of dibromdulcitol in children
✍ Schuler, Dezsõ ;Somló, Pál ;Koós, Rozólia ;Kálmánchey, Rozália ;Paraicz, Ervin 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

## Abstract Dibromdulcitol (Elobromol) has favorable pharmacokinetic parameters for the treatment of brain tumors: high spinal fluid/plasma ratio and long half‐life in spinal fluid. Oral application makes its administration easy. The drug combination vincristine, procarbazine, and dibromdulcitol pr

A phase II evaluation of thiotepa follow
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors
✍ Bassem I. Razzouk; Richard L. Heideman; Henry S. Friedman; Jesse J. Jenkins; Lar 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

## Background: Chemotherapy may be used to delay the need for cranial irradiation in infants and young children with malignant central nervous system (cns) tumors. the polyfunctional alkylator thiotepa (tt) possesses significant in vitro and in vivo activity in many central nervous system tumors. b

Malignant tumors of the kidney, brain, a
Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex
✍ Tahseen Al-Saleem; Lisa L. Wessner; Bernd W. Scheithauer; Kathleen Patterson; E. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 927 KB

## BACKGROUND. The tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by seizures, mental retardation, and benign tumors of the brain, heart, skin, and kidney. Malignant tumors also can occur in patients with tuberous sclerosis, particularly in the kidney, although the

Safety and efficacy of a multicenter stu
Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors
✍ Nancy D. Doolittle; Michael E. Miner; Walter A. Hall; Tali Siegal; E. Jerome Han 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 2 views

The aim of this study was to determine the safety and efficacy of intraarterial chemotherapy with osmotic opening of the blood-brain barrier (BBB) for the treatment of malignant brain tumors when administered across multiple centers.